World of Psychology

Discontinued ADD drug too risky: FDA

By John M. Grohol, PsyD
Founder & Editor-in-Chief

Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.

“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.

In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.


Comments


View Comments / Leave a Comment

This post currently has 2 comments. You can read the comments or leave your own thoughts on our new comments page.

Trackbacks

No trackbacks yet to this post.


    Last reviewed: By John M. Grohol, Psy.D. on 24 Oct 2005
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on February 14, 2012, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/

 

Recent Comments
  • John M. Grohol, PsyD: Hi Dave – There always has been and always will be misdiagnosis when it comes to any...
  • lucrezaborgia: I’m coming late to the discussion so forgive me if I say something that has been brought up in...
  • Harold A. Maio: Patients feel insulted, stigmatized and dismissed I have expereined being insulted. I have...
  • Stacy: I to this day am bullied by my older sister. I’m contemplating legal action.
  • Dave Hommel: Dr G, Thanks for your response. I have met several families in person with children who were incorrectly...
Subscribe to Our Weekly Newsletter



Find a Therapist


Users Online: 3272
Join Us Now!